Indicación de la Hormonoterapia en el Cáncer de Mama

Goldhirsch, 1996, Endocrine therapies of breast cancer, Semin Oncol, 4, 494 1985, Adjuvant chemotherapy for breast cancer, JAMA, 254, 3461, 10.1001/jama.1985.03360240073038 1991, Treatment of early-stage breast cancer, JAMA, 265, 391, 10.1001/jama.1991.03460030097037 Gilck, 1992, Meeting Highlights: Adjuvant therapy for breast cancer, J Natl Cancer Inst, 84, 1479, 10.1093/jnci/84.19.1479 Glick, 1992, Adjuvant therapy of primary breast cancer: 4th International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen Switzerland. Ann Oncol, 3, 801, 10.1093/oxfordjournals.annonc.a058099 Goldhrirsch, 1995, Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer, J Natl Cancer Inst, 87, 1441, 10.1093/jnci/87.19.1441 Goldhrirsch, 1998, Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer, J Natl Cancer Inst, 90, 1601, 10.1093/jnci/90.21.1601 Elleedge, 1998, HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study, Clin Cancer Res, 4, 7 Poon, 1993, Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients, Drug Metab Dispos, 21, 1119 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 Fisher, 1998, Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Projet P-1 study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 Chen, 1999, Epidemiology of contralateral breast cancer, Cancer Epidemiol Biomarkers Prev, 8, 855 1996, Ovarian ablation in early breast cancer: overview of the randomised trials, Lancet, 348, 1189, 10.1016/S0140-6736(96)05023-4 Filipponi, 1996, Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial, Bone, 18, 179, 10.1016/8756-3282(95)00442-4 Hortobagyi, 1998, Treatment of breast cancer, N Engl J Med, 339, 974, 10.1056/NEJM199810013391407 Kimmick, 1995, Current status of endocrine therapy for metastatic breast cancer, Oncology, 9, 877 Stuart, 1996, A randomiced phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer, Eur J Cancer, 32, 1888, 10.1016/0959-8049(96)00191-8 Hayes, 1995, Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer, J Clin Oncol, 13, 2556, 10.1200/JCO.1995.13.10.2556 Crump, 1997, An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer, Breast Cancer Res Treat, 44, 201, 10.1023/A:1005833811584 Buzdar, 1996, Aromatase inhibitors in metastatic breast cancer, Semin Oncol, 23, 28 Buzdar, 1996, Fadrozole HCL (CGS-16949 A) versus megestrol acetate in postmeno-pausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials, Cancer, 77, 2503, 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W Schifeling, 1992, Fluoxymestrona as third line endocrine therapy for advanced breast cancer: a phase II trial of the Piedmont Oncology Association, Am J Clin Oncol, 15, 233, 10.1097/00000421-199206000-00010